Brought to you by 
Novartis buys radiopharmaceuticals company Endocyte for $2.1bn
02 Sep 2020
Executive Summary
Novartis AG agreed to acquire public radiopharmaceuticals firm Endocyte Inc. (targeted cancer therapies and companion imaging agents) for $24 in cash per share (a 55% premium), for an equity value of $2.1bn (an enterprise value of $1.9bn, taking into account the company's cash on its balance sheet).
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis buys radiopharmaceuticals company Endocyte for $2.1bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice